Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575587 | 0.89 | SLC6A2 (0.34) | KDM1ASLC6A2SLC6A4SLC6A3TGFBR1 | |
| SCHEMBL20575901 | 0.88 | SLC6A2 (0.33) | KDM1ASLC6A2SLC6A4SLC6A3HSD11B1 | |
| SCHEMBL20576481 | 0.87 | KDM1A (0.33) | KDM1ASLC6A2SLC6A4SLC6A3HSD11B1 | |
| SCHEMBL20575539 | 0.86 | SLC6A2 (0.32) | KDM1ASLC6A2SLC6A4SLC6A3TGFBR1 | |
| SCHEMBL20575561 | 0.86 | KDM1A (0.35) | KDM1ASLC6A2SLC6A4SLC6A3HSD11B1 | |
| SCHEMBL20575589 | 0.85 | TGFBR1 (0.35) | KDM1ASLC6A2SLC6A4SLC6A3TGFBR1 | |
| SCHEMBL20575667 | 0.83 | KDM1A (0.35) | KDM1ASLC6A2SLC6A4SLC6A3HSD11B1 | |
| SCHEMBL20575191 | 0.83 | SLC6A2 (0.34) | KDM1ASLC6A2SLC6A4SLC6A3HSD11B1 | |
| SCHEMBL20575188 | 0.83 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3TGFBR1NPC1 | |
| SCHEMBL20574820 | 0.82 | NPC1 (0.34) | SLC6A2SLC6A4SLC6A3HSD11B1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | KDM1A 384/4885SLC6A2 3506/4885SLC6A4 3203/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | KDM1A 384/4885SLC6A2 3506/4885SLC6A4 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.